AVAI — AVAI BIO, INC.

—
OTC · Information Technology · IT Services · CIK 1740797 ·
Last close
$0.07
Market Cap
$11.13M
52W High
$0.80
52W Low
$0.07
ADV30
81,533
Next earnings
—
Avaí Bio, Inc. acquires, creates, and develops artificial intelligence (AI) technologies. It also offers information technology (IT) consulting services. The company provides full-stack software development, database management, data integration, project management and cloud services resources. It also offers Avant! AI, a platform that has shown impressive results related to the technology's usage, access, and performance; and InstantFAME. The company was formerly known as Avant Technologies Inc. and changed its name to Avaí Bio, Inc. in February 2026. Avaí Bio, Inc. was incorporated in 2017 and is based in Vilnius, Lithuania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -419,783 -552,041 791,750 83,586 4,014,316
Mar 2026 0 — 14,141 -255,177 572,696 23,145 3,387,851
Dec 2025 0 — -553,727 -553,727 172,912 50,402 2,967,398
Sep 2025 0 — -453,016 -453,016 231,372 91,995 2,532,131

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-1,183,759
Investing CF
$-58,600
Financing CF
$1,315,883
CapEx
$-58,600
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-6,420,060
Inventory
—
Receivables
$60,095
ST Investments
—
EBIT TTM
$-1,588,428
Pretax Income TTM
$-1,813,961
Interest Exp TTM
$60,615
Analysts
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Mar 2026 0 -1,480,191 -1,749,509 572,696 3,387,851 -2,815,155 -1,009,844
Mar 2025 0 -1,532,792 -1,142,115 224,745 1,788,617 -1,563,872 -1,160,610
Mar 2024 0 -2,128,475 -2,128,475 322,014 1,788,580 -1,466,566 -1,322,318
Mar 2023 276,324 -348,933 -348,933 241,460 874,719 -633,259 -54,457
Mar 2022 — — — — — — —

TTM Snapshot

Revenues TTM
$-401,576
NetIncome TTM
$-1,813,961
OpCashFlow TTM
—
Assets (Latest)
$791,750
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
BIRD Smartbird, Inc. $10.73M $1.12 —
STEM STEM, INC. $11.55M $1.20 —
PDC Perpetuals.com Ltd $10.50M $1.55 —
FUSE Fusemachines Inc. $9.77M $0.30 —
BTLN Brightline Interactive, Inc./NV $9.60M $3.27 —

News headlines (Yahoo Finance, 1h cache)

Avaí Bio and Austrianova Announce Publication in Frontiers in Aging Journal Highlighting Novel Cell Encapsulation-Based Approach to Sustained Klotho Delivery
2026-10-28 12:45 · Yahoo
Avaí Bio and Austrianova Hold First Joint Steering Committee Meeting with Ospedale San Raffaele for Diabetes Cell Therapy Program
2026-10-07 12:45 · Yahoo
Avaí Bio and Austrianova Successfully Encapsulate GMP-Quality Klotho-Producing Cells, Achieve Robust Klotho Secretion
2026-09-30 12:45 · Yahoo
Avaí Bio and Austrianova Present Encapsulated Cell Approach to Sustained α-Klotho Delivery at 2026 Klotho Conference
2026-09-24 12:45 · Yahoo
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
2026-07-21 13:00 · Yahoo
Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference
2026-04-07 12:00 · Yahoo
Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes
2026-08-12 12:30 · Yahoo
Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy
2026-05-20 12:45 · Yahoo
Avaí Bio and Austrianova Complete Adventitious Agent Testing of Master Cell Bank, Establish Working Cell Bank for α-Klotho Anti-Aging Therapy
2026-09-15 12:45 · Yahoo
Avaí Bio and Austrianova Reach Agreement for Insulin-Producing Cells with Internationally Acclaimed Partner to Advance Diabetes Therapy
2026-07-21 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.